Блокаторы ренин-ангиотензин- альдостероновой системы при диабетической нефропатии
DOI: https://doi.org/10.29296/25877305-2021-10-03
Номер журнала:
10
Год издания:
2021
Диабетическая нефропатия (ДНП) ассоциирована с высоким риском развития терминальной стадии почечной
недостаточности и неблагоприятным сердечно-сосудистым прогнозом, что требует жесткого контроля уровней АД и
гликемии у данных пациентов. Обсуждается нецелесообразность использования единого термина «ДНП» для
обозначения всех случаев хронической болезни почек (ХБП) у пациентов с сахарным диабетом (СД), поскольку
примерно у 30–50% больных СД обоих типов при скорости клубочковой фильтрации
Ключевые слова:
клиническая нефрология
сахарный диабет
диабетическая нефропатия
блокаторы ренин-ангиотензин-альдостероновой системы
Для цитирования
А.Э. Багрий, М.В. Хоменко, Е.С. Михайличенко Блокаторы ренин-ангиотензин- альдостероновой системы при диабетической нефропатии
. Врач, 2021; (10): 16-24 https://doi.org/10.29296/25877305-2021-10-03Список литературы:
- 1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й вып. (доп.). Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. Сахарный диабет. 2019; 22 (S1): 1–213 [Standards of specialized diabetes care. 9th ed.(revised). Ed. by I.I. Dedov, M.V. Shestakova, A.Yu. Maiorov. Diabetes mellitus. 2019; 22 (S1): 1–213 (in Russ.)]. DOI: 10.14341/DM221S1
- 2. Архипов Е.В., Ощепкова О.Б., Синеглазова А.В. и др. Поражение почек при метаболических нарушениях (ожирение, метаболический синдром, диабет, подагра и др.). Нефрология. 2019; 23 (S1): 75–88 [Arkhipov E.V., Oschepkova O.B., Sineglazova A.V. et al. Kidney damage in metabolic disorders (obesity, metabolic syndrome, diabetes mellitus, gout, etc.). Nephrology (Saint-Petersburg). 2019; 23 (S1): 75–88 (in Russ.)]. DOI: 10.36485/1561-6274-2019-23-5-75-88
- 3. Eknoyan G., Lameire N., Wheeler D.C. et al. KDIGO Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease. URL: https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-Management-in-CKD_Public-Review.pdf
- 4. Pugliese G., Penno G., Natali A. et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on «The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function». J Nephrol. 2020; 33 (1): 9–35. DOI: 10.1007/s40620-019-00650-x
- 5. Neumiller J.J., Bakris G., Cefalu W.T. et al. Professional Practice Committee: Standards of Medical Care in Diabetes, 2020. Diabetes Care. 2020; 43 (S1): S3. DOI: 10.2337/dc20-SPPC
- 6. Rawshani A., Rawshani A., Franzen S. et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018; 379: 633–44. DOI: 10.1056/NEJMoa1800256
- 7. Маркова Т.Н., Садовская В.В., Беспятова М.Ю. Современные возможности диагностики хронической болезни почек при сахарном диабете. Сахарный диабет. 2017; 20 (6): 454–60 [Markova T.N., Sadovskaya V.V., Bespyatova M.Y. Modern methods of diagnosing chronic kidney disease in patients with diabetes mellitus. Diabetes mellitus. 2017; 20 (6): 454–60 (in Russ.)]. DOI: https://doi.org/10.14341/DM9268
- 8. Добронравов В.А., Шестакова М.В. Диабетическая нефропатия. В кн.: Нефрология. Национальное руководство. Под ред. Н.А. Мухина. М.: ГЭОТАР-Медиа, 2016; c. 337–49 [Dobronravov V.A., Shestakova M.V. Diabeticheskaya nefropatiya. In: Nefrologiya. Natsional’noye rukovodstvo. Ed. N.A. Mukhin. M.: GEOTAR-Media, 2016; p. 337–49 (in Russ.)].
- 9. Alicic R.Z., Rooney M.T., Tuttle K.R. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017; 12 (12): 2032–45. DOI: 10.2215/CJN.11491116
- 10. Kopel J., Pena-Hernandez C., Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes. 2019; 10 (5): 269–79. DOI: 10.4239/wjd.v10.i5.269
- 11. Doshi S.M., Friedman A.N. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017; 12: 1366–73. DOI: 10.2215/CJN.11111016
- 12. Sarnak M.J., Amann K., Bangalore S. et al. Chronic Kidney Disease and Coronary Artery Disease. J Am Coll Cardiol. 2019; 74 (14): 1823–38. DOI: 10.1016/j.jacc.2019.08.1017
- 13. Томилина Н.А. Хроническая болезнь почек. Избранные главы нефрологии. М.: ГЭОТАР-Медиа, 2017; 136 с. [Tomilina N.A. Khronicheskaya bolezn’ pochek. Izbranniye glavi nefrologii. M.: GEOTAR-Media, 2017; 136 р. (in Russ.)].
- 14. Bilo H., Coentrao L., Couchoud C. et al. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR
- 15. Farrah F.E., Dhillon B., Keane P.A. et al. The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. Kidney Int. 2020; 98 (2): 323–42. DOI: 10.1016/j.kint.2020.01.039
- 16. Georgianos P.I., Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018; 93 (2): 325–34. DOI: 10.1016/j.kint.2017.08.038
- 17. Imai E., Chan J.C., Ito S. et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011; 54 (12): 2978–86. DOI: 10.1007/s00125-011-2325-z
- 18. Ruiz-Ortega M., Rodrigues-Diez R.R., Lavoz C. et al. Special Issue «Diabetic Nephropathy: Diagnosis, Prevention and Treatment». J Clin Med. 2020; 9 (3): 813. DOI: 10.3390/jcm9030813
- 19. Yacoub R., Campbell K.N. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2015; 8: 29–40. DOI: 10.2147/IJNRD.S37893
- 20. Heerspink H.J.L., Kosiborod M., Inzucchi S.E. et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94 (1): 26–39. DOI: 10.1016/j.kint.2017.12.027
- 21. Gorriz J.L., Navarro-Gonzalez J.F., Ortiz A. et al. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant. 2020; 35: i13–i23. DOI: 10.1093/ndt/gfz237
- 22. Keri K.C., Samji N.S., Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect. 2018; 8 (4): 200–7. DOI: 10.1080/20009666.2018.1500423
- 23. Shivakumar O., Sattar N, Wheeler D.C. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant. 2020; 35 (S1): i43–i47. DOI: 10.1093/ndt/gfz292
- 24. Sulaiman M.K. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 2019; 11: 7. DOI: 10.1186/s13098-019-0403-4
- 25. Gomez L.A., Lei Y., Devarapu S.K. et al. The diabetes pandemic suggests unmet needs for «CKD with diabetes» in addition to «diabetic nephropathy» – implications for pre-clinical research and drug testing. Nephrol Dial Transplant. 2018; 33 (8): 1292–304. DOI: 10.1093/ndt/gfx219
- 26. Смирнов А.В., Добронравов В.А., Кисина А.А. и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология. 2015; 19 (1): 67–77 [Smirnov A.V., Dobronravov V.A., Kisina A.A. et al. Clinical practice guideline for diagnostics and treatment of diabetic nephropathy. Nephrology (Saint-Petersburg). 2015; 19 (1): 67–77 (in Russ.)].
- 27. Bakris G.L, Agarwal R, Anker S.D. et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50 (5): 333–44. DOI: 10.1159/000503713
- 28. Anders H.-J., Davis J.M., Thurau K. Nephron Protection in Diabetic Kidney Disease. N Engl J Med. 2016; 375 (21): 2096–8. DOI: 10.1056/NEJMcibr1608564
- 29. Williams B., Mancia G., Spiering W. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
- 30. Bateman B.T., Patorno E., Desai R.J. et al. Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol. 2017; 129 (1): 174–84. DOI: 10.1097/AOG.0000000000001775
- 31. Bullo M., Tschumi S., Bucher B.S. et al. Pregnancy outcome following exposure to angiotensin- converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60 (2): 444–50. DOI: 10.1161/HYPERTENSIONAHA.112.196352
- 32. Coutrot M., Depret F., Legrand M. Tailoring treatment of hyperkalemia. Nephrol Dial Transplant. 2019; 34 (S3): iii62–iii68. DOI: 10.1093/ndt/gfz220
- 33. Seliger S.L. Hyperkalemia in patients with chronic renal failure. Nephrol Dial Transplant. 2019; 34 (S3): iii12–iii18. DOI: 10.1093/ndt/gfz231
- 34. Hou J., Xiong W., Cao L. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther. 2015; 37 (9): 2086–103. DOI: 10.1016/j.clinthera.2015.05.508
- 35. Bianchi S., Regolisti G. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrol Dial Transplant. 2019; 34 (S1): iii51–iii61. DOI: 10.1093/ndt/gfz213
- 36. Hunter R.W., Bailey M.A. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019; 34 (S3): iii2–iii11. DOI: 10.1093/ndt/gfz206
- 37. Trevisan M., de Deco P., Xu H. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018; 20: 1217–26. DOI: 10.1002/ejhf.1199
- 38. Pitt B., Bakris G.L., Weir M.R. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018; 5 (4): 592–602. DOI: 10.1002/ehf2.12292
- 39. Clase C.M., Carrero J.-J., Ellison D.H. et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020; 97 (1): 42–61. DOI: 10.1016/j.kint.2019.09.018
- 40. Liu L.C., Schutte E., Gansevoort R.T. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015; 24 (8): 1123–35. DOI: 10.1517/13543784.2015.1059819